Health
Britain’s Access to New Drugs Could ‘Totally Shrink,’ Says Astra Chief
- CEO Pascal Soriot argues Britain must change rules over access
- Patients will get hurt if reforms are not made, Soriot adds
This article is for subscribers only.
AstraZeneca Plc Chief Executive Officer Pascal Soriot has a warning for Britain’s new Labour government: improve access to innovative pharmaceuticals or life sciences companies won’t invest in the country.
Soriot warned Thursday that if the UK doesn’t change the way it assesses new drugs such as Astra’s cancer treatment Enhertu, patients will continue to miss out and other drugmakers with looser ties to Britain will take their money elsewhere.